Industry: Healthcare
Published Date: January-2019
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 201
Report ID: PMRREP27115
The renal anemia treatment market value was estimated at US$8.0 Bn in 2024 and is expected to be valued at US$12.3 Bn by 2031. The market for military antennas is predicted to reach an expanding, good CAGR of 6.3% from 2024 to 2031.
Key Highlights of the Market
|
Attributes |
Key Insights |
|
Market Size (2024E) |
US$8.0 Bn |
|
Projected Market Value (2031F) |
US$12.3 Bn |
|
Forecast Growth Rate (CAGR 2024 to 2031) |
6.3% |
|
Historical Growth Rate (CAGR 2018 to 2023) |
5.6% |
As per the renal anemia treatment market outlook, the early adoption of advanced treatment options and favorable reimbursement policies in the US are expected to drive the industry in the coming years.
According to the American Family Physician, the prevalence of iron deficiency anemia varies across different demographic groups, with higher rates in black and Mexican-American women (20%), non-Hispanic white women (9-12%), and adult men (nearly 2%).
Additionally, about 9% of patients over 65 with this condition have gastrointestinal cancer. As these numbers continue to rise, the demand for drugs for iron anemia treatment is projected to increase.
The increasing prevalence of iron deficiency among individuals in the UK is projected to drive the renal anemia treatment market sales. Factors such as innovative technologies and evolving lifestyle patterns are also expected to contribute to the demand for drugs to treat aplastic anemia in the UK.
Additionally, the rise in per capita income and the entry of established companies have led to a surge in research and development activities. The increasing number of new product launches further fuels the market.
The medications segment is poised to dominate the market, fueled by the increasing utilization of biologics such as Erythropoietin Stimulating Agents (ESAs) in sickle cell anemia treatment.
Moreover, the growing number of FDA approvals for biosimilars is expected to provide numerous advantages to patients with chronic kidney disease-related anemia.
With easy patient, access to unique ESAs and a high demand for cost-effective biosimilar medications, key renal anemia treatment market players are presented with new growth opportunities.
The normocytic anemia segment is projected to experience significant growth in the anemia treatment market, fueled by the increasing prevalence of congenital disorders such as sickle cell disease and various chronic diseases.
Conditions like thyroiditis, kidney disease, rheumatoid arthritis, and cancer can also contribute to normocytic anemia. The rising number of individuals affected by these chronic diseases globally presents an opportunity for acute anemia treatment options. This trend is expected to drive demand and create growth opportunities for key renal anemia treatment market players.
The market overview shows that institutional pharmacies dominated the distribution channel, accounting for approximately 55.9% of the market share in 2022. The convenient accessibility of a wide range of medications for sickle cell anemia treatment drives the segment's growth.
Forecasts also indicate that retail pharmacies and mail-order pharmacies will hold 38.0% and 6.1% of the market share, respectively, in 2022. The personalized advice provided by retail pharmacists and the cost-effectiveness of mail-order pharmacies contribute to their sales growth.
The renal anemia treatment market refers to the market for therapies and treatments aimed at managing anemia in patients with chronic kidney disease (CKD).
According to a market research report, the sector was valued at approximately US$6.1 Bn in 2019. It is projected to reach US$8.0 Bn in 2024 and further grow to US$12.3 Bn by 2031. The market is expected to experience a CAGR of 5.6% from 2019 to 2023 and a CAGR of 6.3% from 2024 to 2031.
Several market trends are influencing the industry growth. The increasing prevalence of CKD globally is a significant driver for the renal anemia treatment market.
The advancements in treatment options for renal anemia include the development of new drugs and therapies that target the underlying causes of anemia in CKD patients. These innovations are expected to drive renal anemia treatment market growth and improve patient outcomes.
There is a growing awareness of anemia as a complication of CKD, leading to increased diagnosis and treatment. Pharmaceutical companies and research institutions are investing in research and development activities to discover new treatment options and improve existing therapies for renal anemia.
Further, the market update shows that investment is expected to drive innovation and contribute to expansion. Additionally, as the global population continues to age, the prevalence of renal anemia is expected to increase, driving the demand for treatment options.
The renal anemia treatment market forecast has shown steady growth in recent years and is expected to continue its upward trajectory in the future. In 2019, the global market share was valued at approximately US$6.1 Bn.
The market is projected to reach US$7.6 Bn by 2023, representing a compound annual growth rate (CAGR) of 5.6% from 2019 to 2023. Looking further ahead, the market is expected to reach US$12.3 Bn by 2031, with a projected CAGR of 6.3% from 2024 to 2031.
The renal anemia treatment market concentration highlights the increasing prevalence of CKD globally, which is a significant driver for the industry.
The market is witnessing advancements in treatment options for renal anemia. These advancements include the development of new drugs and therapies that target the underlying causes of anemia in CKD patients. These innovations are expected to drive market growth and improve patient outcomes.
The growing awareness of anemia as a complication of CKD is leading to increased diagnosis and treatment. Technological advancements, such as AI and ML algorithms, are enhancing the accuracy and efficiency of diagnostic and treatment approaches in renal anemia. These advancements are expected to contribute to the growth of the market.
Additionally, market trends and pharmaceutical companies' and research institutions' efforts in research and development activities to discover new treatment options are expected to drive innovation and contribute to market growth.
Advancements in Treatment Options
The development of novel erythropoiesis-stimulating agents (ESAs) and iron supplementation therapies has revolutionized treatment protocols, offering more effective and targeted approaches to managing renal anemia. These advancements improve therapeutic outcomes and contribute towards market growth.
Increasing Prevalence of CKD
The rising incidence of CKD globally is a significant driver for the renal anemia treatment market's expansion. As CKD is a common condition that often leads to anemia, the growing number of CKD cases creates a higher demand for effective treatment options, which ultimately pushes the renal anemia market sales.
Growing Awareness and Diagnosis
There is a growing awareness of anemia as a complication of CKD, leading to increased diagnosis and treatment. Healthcare providers and patients are becoming more educated about the condition, resulting in a higher demand for renal anemia treatments. Further, innovative diagnosis options are fueling the market demand.
Stringent Regulatory Requirements
The renal anemia treatment market is subject to strict regulations and guidelines imposed by regulatory authorities to ensure patient safety and efficacy of therapies. These stringent requirements can pose challenges for pharmaceutical companies, leading to delays in the development and approval of new treatments.
Compliance with regulatory standards and the lengthy approval process can hinder the introduction of innovative therapies into the industry, potentially limiting the growth opportunities in the renal anemia treatment market.
Limited Access to Healthcare
In some regions, particularly low-income countries or underserved areas, there may be limited access to healthcare facilities and resources. This lack of access can result in delayed diagnosis and treatment of renal anemia.
Additionally, limited healthcare infrastructure and affordability issues may restrict patients' ability to receive appropriate treatment, hindering the market revenue. Efforts to improve healthcare access and affordability in these regions are necessary to address this impediment.
Personalized Medicine and Precision Therapies
The advancements in genetic and molecular research are paving the way for personalized medicine in the field of renal anemia treatment. By understanding the unique genetic makeup and molecular characteristics of individual patients, healthcare providers can develop targeted therapies that are tailored to their specific needs.
The personalized approach has the potential to improve treatment efficacy, reduce adverse effects, and enhance patient outcomes, presenting significant renal anemia treatment market opportunities.
Emerging Markets, and Improving Healthcare Structures
The market has significant growth potential in emerging markets and untapped regions. These regions often have a high burden of chronic kidney disease and anemia, coupled with a growing middle-class population and improving healthcare infrastructure.
As these regions witness economic growth and increased healthcare access, the demand for renal anemia treatment is expected to rise, presenting opportunities for the renal anemia market expansion and penetration into new markets.
The renal anemia treatment market manufacturers are pursuing growth through acquisitions and innovation. The competitive landscape is strengthened by the presence of startups offering unique solutions.
To stay competitive, market companies in this market are making significant investments to expand production capabilities and enhance technological features. Their objective is to develop innovative functionalities and seamlessly integrate technologies into this rapidly evolving sector. This strategic approach supports successful concentration, entry, and widespread adoption of renal anemia treatments.
Recent Industry Developments
In March 2024, the US Food and Drug Administration (FDA) approved Akebia Therapeutics for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. The drug is now approved in 37 countries.
In February 2023, Astellas Pharma Inc. introduced a new treatment for adults with anemia associated with chronic kidney disease (CKD), a progressive disease characterized by gradual loss of kidney function that may eventually lead to kidney failure or end-stage kidney disease. CKD has a significant unmet medical need in Egypt, ranking fifth among the leading causes of death in the country. The new treatment activates the body's natural response to reduced oxygen levels in the blood, improving iron absorption and mobilization and increasing red cell production.
|
Attributes |
Details |
|
Forecast Period |
2024 to 2031 |
|
Historical Data Available for |
2018 to 2023 |
|
Market Analysis |
US$ Billion for Value |
|
Key Country Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Treatment
By Disease
By Distribution Channel
By Region
To know more about delivery timeline for this report Contact Sales
The market for blister packaging is anticipated to grow from US$8.0 Bn in 2024 to US$12.3 Bn by 2031.
The increasing prevalence of CKD globally, advancements in treatment options, and growing awareness of anemia as a CKD complication are augmenting the market growth.
Amgen Inc. Johnson & Johnson, Roche Holding AG, Fresenius Medical Care AG & Co. KGaA, and Pharmacosmos A/S are some key industry players.
Challenges like strict regulations and guidelines and strict regulations and guidelines are restraining industry expansion.
The advancements in genetic and molecular research and improving healthcare infrastructure are the key opportunities in the market.
